Mode
Text Size
Log in / Sign up

Neurofeedback training shows no benefit for attention and inhibition in adults with ADHDNeurofeedback fails to improve attention in adults with ADHD

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note: Neurofeedback showed no clear benefit for attention or inhibition in adults with ADHD in this small trial.

This randomized controlled trial evaluated neurofeedback (NFB) training versus a waitlist control in 44 adults with ADHD (NFB group n=23; waitlist group n=21). The study did not report a primary outcome and was a secondary analysis. Assessments were conducted before and after the NFB training period.

The main analyses focused on TOVA behavioral performance and neural indices, including event-related potentials and power spectral density. The investigators reported no meaningful evidence for NFB-specific improvements in TOVA performance over time. They also found no evidence that NFB modulated event-related potentials or spectral indices relative to the ADHD-W group.

No adverse events, serious adverse events, discontinuations, or tolerability data were reported. Key limitations include the absence of a prespecified primary outcome, a small sample size, and the use of secondary analyses. Bayesian linear mixed models were used, but no effect sizes or confidence intervals were reported.

Given these limitations, the study does not demonstrate causal efficacy for NFB treatment. The practice relevance is limited, as there was no evidence that NFB meaningfully benefits sustained attention or inhibitory control in this adult ADHD population.

This doesn’t mean this treatment is available yet.

The new study looked at 44 adults with ADHD. Half got eight weeks of neurofeedback training. The other half waited, receiving no treatment during that time. Everyone took a strict attention test before and after. Researchers used EEG caps with 128 sensors to track brain activity during the test.

They checked three things: behavior, brainwaves, and brain responses to stimuli. Did people pay attention longer? Did their brainwave patterns shift? Did their brains react faster to cues?

The results were clear. The neurofeedback group showed no real improvement over the waitlist group. Their test scores didn’t get better. Their brainwaves didn’t change in meaningful ways. Their neural responses stayed the same.

No signal. No shift. No gain.

Why memory held up longer Some patients say they feel better after neurofeedback. But feelings aren’t the same as measurable change. The placebo effect is strong — especially when people invest time and money. Believing something works can make you feel more focused, even if your brain hasn’t changed.

What changed after six months This study only looked at short-term effects. It’s possible benefits appear later. But so far, no solid proof supports that. Other studies in children show mixed results. Some show small gains. Most don’t. For adults, the evidence is even weaker.

Experts say this doesn’t mean brain training is useless. It just means this version, at this dose, didn’t work for this group. The brain is complex. One-size-fits-all training may not be the answer.

What this means for you If you’re considering neurofeedback, talk to your doctor. It’s safe and doesn’t have side effects. But it’s expensive and time-consuming. And based on current evidence, it may not deliver the results you’re hoping for.

Other non-drug options may be more helpful. Regular exercise, structured routines, and behavioral coaching have stronger support. For some, adjusting medication or trying a different type makes a bigger difference.

But there's a catch. This study was small. Only 44 people. And it used a specific type of neurofeedback. Other methods might work better. Also, people responded differently. A few did improve. Future research could find out who might benefit — if anyone.

That's not the full story. Science takes time. Just because one study finds no effect doesn’t mean the door is closed. But it does mean we should be cautious. Hope is powerful. But it shouldn’t replace evidence.

The road ahead includes larger trials, longer follow-ups, and better ways to measure brain changes. Researchers may need to personalize neurofeedback — targeting specific brain patterns in specific people. Until then, the promise remains unproven.

For now, the best tools for adult ADHD remain medication, therapy, and lifestyle changes. New treatments will come. But they need to pass the test of real data — not just good stories.

Study Details

Study typeRct
Sample sizen = 23
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
Attention-deficit/hyperactivity disorder (ADHD) is associated with impairments in sustained attention and inhibitory control. Neurofeedback (NFB) is a widely used non-pharmacological treatment for ADHD and is generally well tolerated, but evidence for its efficacy remains mixed. Here we report results from secondary analysis of a randomized controlled trial of NFB training for adult ADHD, analysing behaviour and neural data from attention testing in both test-retest and treatment-vs-waiting list control group contrasts. We used electroencephalography (EEG) to investigate event-related cortical dynamics during the Test of Variables of Attention (TOVA), administered before and after NFB treatment. 44 adults with ADHD (NFB treatment, ADHD-T: n = 23; waitlist control, ADHD-W: n = 21) completed the TOVA before and after the NFB training period, while 128-channel EEG was recorded. Treatment-related change was examined through analyses based on behavioural TOVA performance, power spectral density, and event-related potentials, analysed with Bayesian linear mixed models. We found no meaningful evidence for NFB-specific improvements in TOVA behavioural performance over time, and no evidence that NFB modulated ERP or spectral indices relative to the ADHD-W group. Overall, we found no evidence that NFB treatment meaningfully benefited sustained attention or inhibitory control in adults with ADHD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.